Literature DB >> 17430876

Refractory neurosarcoidosis responsive to infliximab.

Christopher Kobylecki1, Sandip Shaunak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17430876

Source DB:  PubMed          Journal:  Pract Neurol        ISSN： 1474-7758


× No keyword cloud information.
  7 in total

1.  Long-term outcomes of refractory neurosarcoidosis treated with infliximab.

Authors:  Fleur Cohen Aubart; Diane Bouvry; Damien Galanaud; Caroline Dehais; Guillaume Mathey; Dimitri Psimaras; Julien Haroche; Corinne Pottier; Miguel Hie; Alexis Mathian; Hervé Devilliers; Hilario Nunes; Dominique Valeyre; Zahir Amoura
Journal:  J Neurol       Date:  2017-03-04       Impact factor: 4.849

Review 2.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 3.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations.

Authors:  J Chad Hoyle; Courtney Jablonski; Herbert B Newton
Journal:  Neurohospitalist       Date:  2014-04

5.  Treatment of sarcoid granulomatous interstitial nephritis with adalimumab.

Authors:  Roopali Gupta; Lisa Beaudet; Jack Moore; Tulsi Mehta
Journal:  NDT Plus       Date:  2009-01-06

6.  Neurosarcoidosis in a Tertiary Referral Center: A Cross-Sectional Cohort Study.

Authors:  Sonja E Leonhard; Daan Fritz; Filip Eftimov; Anneke J van der Kooi; Diederik van de Beek; Matthijs C Brouwer
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 7.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.